1616829-07-2

Upstream product

• 1616828-53-5 6-bromo-8-methoxy-3H-quinazolin-4-one 
• 1215634-37-9 4-bromo-2-carboxy-6-methoxybenzenamine hydrobromide 
• 1073371-76-2 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine hydrochloride 
• 1616828-60-4 6-bromo-8-(2-trimethylsilanyl-ethoxymethoxy)-3-(2-trimethylsilanyl-ethoxymethyl)-3H-quinazolin-4-one 
• 76-05-1 trifluoroacetic acid 

Relevant academic research and scientific papers

COMT INHIBITORS

The present invention relates to compounds of formula (I), wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.